Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Agnieszka Zagórska. (2020) Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present). Expert Opinion on Therapeutic Patents 30:2, pages 147-157.
Read now
Read now
Articles from other publishers (26)
Gbenga Shogbesan, Harry W. Schroeder, Domnique Newallo & Lance T. Hall. 2022. Gastrointestinal Cancers. Gastrointestinal Cancers
1
13
.
Gaurav Doshi, Nirav Bhatia, Hemen Ved, Aditya Pandya, Duttraj Kulkarni, Janhavi Naik, Tejal Bandiwadekar, Angel Godad & Pravin Kale. (2023) Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic
Approach in the Treatment of Schizophrenia. CNS & Neurological Disorders - Drug Targets 22:7, pages 994-1007.
Crossref
Crossref
Michał Załuski, Tadeusz Karcz, Anna Drabczyńska, Christin Vielmuth, Agnieszka Olejarz-Maciej, Monika Głuch-Lutwin, Barbara Mordyl, Agata Siwek, Grzegorz Satała, Christa E. Müller & Katarzyna Kieć-Kononowicz. (2023) Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases. Biomolecules 13:7, pages 1079.
Crossref
Crossref
Sarah K. Royse, Brian J. Lopresti, Chester A. Mathis, Savannah Tollefson & Rajesh Narendran. (2022) Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders. Journal of Neurochemistry 164:3, pages 401-443.
Crossref
Crossref
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov, Wen Liu & Helgi B. Schiöth. (2022) Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Frontiers in Pharmacology 13.
Crossref
Crossref
Huiyi Wei, Junjie Wei, Shaojuan Zhang, Shiliang Dong, Guocong Li, Wenqing Ran, Chenchen Dong, Weibin Zhang, Chao Che, Wenzhao Luo, Hao Xu, Zhiyong Dong, Jinghao Wang & Lu Wang. (2022) Easily automated radiosynthesis of [18F]P10A-1910 and its clinical translation to quantify phosphodiesterase 10A in human brain. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Tanja Veselinović & Irene Neuner. (2022) Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 36:8, pages 819-858.
Crossref
Crossref
Rayanne Poletti Guimarães, Danilo Leandro Ribeiro, Keila Bariotto Dos Santos, Carlos Henrique Zanello Talarico, Lívea Dornela Godoy & Fernando E. Padovan-Neto. (2022) Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia. Pharmaceuticals 15:8, pages 947.
Crossref
Crossref
Zhiwei Xiao, Huiyi Wei, Yi Xu, Ahmed Haider, Junjie Wei, Shiyu Yuan, Jian Rong, Chunyu Zhao, Guocong Li, Weibin Zhang, Huangcan Chen, Yuefeng Li, Lingling Zhang, Jiyun Sun, Shaojuan Zhang, Hai-Bin Luo, Sen Yan, Qijun Cai, Lu Hou, Chao Che, Steven H. Liang & Lu Wang. (2022) Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination. Acta Pharmaceutica Sinica B 12:4, pages 1963-1975.
Crossref
Crossref
Yuqi Gao, Ju Huang, Qian Zhou, Runduo Liu, Sirui Zhang, Chen Zhang, Yi-You Huang, Zhe Li, Ling Huang, Deyan Wu, Yinuo Wu, Lehui Xiao, Lei Guo & Hai-Bin Luo. (2021) Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells. ACS Chemical Biology 16:5, pages 857-863.
Crossref
Crossref
Frank S. Menniti, Thomas A. Chappie & Christopher J. Schmidt. (2021) PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?. Frontiers in Neuroscience 14.
Crossref
Crossref
Yuncong Yang, Sirui Zhang, Qian Zhou, Chen Zhang, Yuqi Gao, Hao Wang, Zhe Li, Deyan Wu, Yinuo Wu, Yi-You Huang, Lei Guo & Hai-Bin Luo. (2020) Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharmaceutica Sinica B 10:12, pages 2339-2347.
Crossref
Crossref
Misae Takakuwa, Yumi Watanabe, Takeaki Saijo, Meguru Murata, Jun Anabuki, Tomoaki Tezuka, Saori Sato, Koki Kojima & Kenji Hashimoto. (2020) Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats. Pharmacology Biochemistry and Behavior 196, pages 172972.
Crossref
Crossref
Michy P. Kelly, Pim R.A. Heckman & Robbert Havekes. (2020) Genetic manipulation of cyclic nucleotide signaling during hippocampal neuroplasticity and memory formation. Progress in Neurobiology 190, pages 101799.
Crossref
Crossref
Mohammed Shahid, Joanna C. Neill & John Hutchison. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
35
68
.
Yan-Fa Yu, Chen Zhang, Yi-You Huang, Sirui Zhang, Qian Zhou, Xiangmin Li, Zengwei Lai, Zhe Li, Yuqi Gao, Yinuo Wu, Lei Guo, Deyan Wu & Hai-Bin Luo. (2020) Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chemical Neuroscience 11:7, pages 1058-1071.
Crossref
Crossref
Arjan Blokland, Pim Heckman, Tim Vanmierlo, Rudy Schreiber, Dean Paes & Jos Prickaerts. (2019) Phosphodiesterase Type 4 Inhibition in CNS Diseases. Trends in Pharmacological Sciences 40:12, pages 971-985.
Crossref
Crossref
Misae Takakuwa, Yumi Watanabe, Kiichi Tanaka, Taketoshi Ishii, Kenta Kagaya, Hiroyuki Taniguchi, Jun Kotera & Kenji Hashimoto. (2019) Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents. Pharmacology Biochemistry and Behavior 185, pages 172757.
Crossref
Crossref
Hugo Geerts & James E. Barrett. (2019) Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D. Frontiers in Neuroscience 13.
Crossref
Crossref
Shuichi Yanai & Shogo Endo. (2018) PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment. Molecular Neurobiology 56:6, pages 4306-4316.
Crossref
Crossref
Anthony A Grace & Felipe V Gomes. (2019) The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. Schizophrenia Bulletin 45:1, pages 148-157.
Crossref
Crossref
Giulia Boscutti, Eugenii A Rabiner & Christophe Plisson. (2019) PET Radioligands for imaging of the PDE10A in human: current status. Neuroscience Letters 691, pages 11-17.
Crossref
Crossref
Jing Shi, Huaxia Liu, Jianchun Pan, Jie Chen, Nianping Zhang, Kaiping Liu, Ning Fei, James M. O’Donnell, Han-Ting Zhang & Ying Xu. (2018) Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice. Psychopharmacology 235:8, pages 2377-2385.
Crossref
Crossref
P.R.A. Heckman, A. Blokland, E.P.P. Bollen & J. Prickaerts. (2018) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. Neuroscience & Biobehavioral Reviews 87, pages 233-254.
Crossref
Crossref
Ana García, José Brea, Alejandro González-García, Concepción Pérez, María Isabel Cadavid, María Isabel Loza, Ana Martinez & Carmen Gil. (2017) Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules 22:9, pages 1472.
Crossref
Crossref
Ana M García, Irene G Salado, Daniel I Perez, José Brea, Jose A Morales-GarcíaAlejandro González-García, María Isabel Cadavid, María Isabel Loza, Francisco Javier Luque, Ana Perez-CastilloAna Martinez & Carmen Gil. (2017) Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson’s disease. Future Medicinal Chemistry 9:8, pages 731-748.
Crossref
Crossref